CN113440557A - 用于治疗便秘的中药组合物及其制备方法 - Google Patents
用于治疗便秘的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN113440557A CN113440557A CN202110919165.9A CN202110919165A CN113440557A CN 113440557 A CN113440557 A CN 113440557A CN 202110919165 A CN202110919165 A CN 202110919165A CN 113440557 A CN113440557 A CN 113440557A
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- chinese medicine
- medicine composition
- treating constipation
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 72
- 239000003814 drug Substances 0.000 title claims abstract description 69
- 206010010774 Constipation Diseases 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 241000005787 Cistanche Species 0.000 claims abstract description 8
- 241000382455 Angelica sinensis Species 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 3
- 239000008187 granular material Substances 0.000 claims description 29
- 239000002775 capsule Substances 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 9
- 238000004108 freeze drying Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000001291 vacuum drying Methods 0.000 claims description 5
- 244000183685 Citrus aurantium Species 0.000 claims description 4
- 235000007716 Citrus aurantium Nutrition 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 230000003071 parasitic effect Effects 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 3
- 241000208173 Apiaceae Species 0.000 claims description 2
- 241001113846 Loganiaceae Species 0.000 claims description 2
- 241000218231 Moraceae Species 0.000 claims description 2
- 241000308150 Orobanchaceae Species 0.000 claims description 2
- 235000013399 edible fruits Nutrition 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 241001093501 Rutaceae Species 0.000 claims 1
- 240000001866 Vernicia fordii Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 42
- 230000006870 function Effects 0.000 abstract description 16
- 241000345998 Calamus manan Species 0.000 abstract description 4
- 235000012950 rattan cane Nutrition 0.000 abstract description 4
- 230000002040 relaxant effect Effects 0.000 abstract description 4
- 230000007423 decrease Effects 0.000 abstract description 3
- 230000003871 intestinal function Effects 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 23
- 230000008602 contraction Effects 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 21
- 239000002245 particle Substances 0.000 description 21
- 230000000968 intestinal effect Effects 0.000 description 20
- 241000700199 Cavia porcellus Species 0.000 description 18
- 229940079593 drug Drugs 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 210000003405 ileum Anatomy 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 230000013872 defecation Effects 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- 241000316342 Taxillus Species 0.000 description 9
- 210000001072 colon Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 210000002429 large intestine Anatomy 0.000 description 6
- 239000008141 laxative Substances 0.000 description 6
- 210000003608 fece Anatomy 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 239000010871 livestock manure Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000001543 purgative effect Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 241000125175 Angelica Species 0.000 description 4
- 235000001287 Guettarda speciosa Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 241000336291 Cistanche deserticola Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000037020 contractile activity Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 210000001187 pylorus Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 2
- 150000004056 anthraquinones Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 230000007659 motor function Effects 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001141 propulsive effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000981770 Buddleja asiatica Species 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241001136860 Ficus tikoua Species 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- -1 microecologics Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 229940052490 naringin Drugs 0.000 description 1
- 229930019673 naringin Natural products 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 231100000191 repeated dose toxicity Toxicity 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/56—Loganiaceae (Logania family), e.g. trumpetflower or pinkroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及中药技术领域,具体涉及一种用于治疗便秘的中药组合物及其制备方法。所述的治疗便秘的中药组合物,由以下重量份数的原料制成:七里香寄生25~40份,地板藤寄生15‑20份,肉苁蓉1~5份,当归1~5份,枳壳1~3份。本发明的中药组合物具有很好的通便作用,可有效治疗便秘,副作用小,尤其适合顽固性便秘、功能性便秘及肠道功能衰退的病人;本发明还提供其制备方法。
Description
技术领域
本发明涉及中药技术领域,具体涉及一种用于治疗便秘的中药组合物及其制备方法。
背景技术
随着经济的发展及生活质量的提高,便秘的患病率逐年上升,其中一些患者久治不愈发展为顽固性便秘。顽固性便秘多发生于老年人,是指一种长期的、慢性功能性便秘。顽固性便秘的实质是慢性的不全性肠梗阻,临床便秘可分为结肠慢传输型便秘、出口梗阻型便秘和两者并存的混合型便秘。便秘给患者带来很大的痛苦并且严重影响病人的生活质量,尤其对于老年患者的危害更加严重,常因为排便费力诱发冠心病、心绞痛甚至心肌梗死等。
目前便秘的治疗药物主要为泻药、促动力药、微生态制剂、钙通道阻滞剂、灌肠和栓剂等。现代医学以对症为主,药物繁多,易产生耐药性,病情易复发,若长期大量应用含蒽醌类及其衍生物的接触性泻剂,可形成“泻剂结肠”,从而加重便秘的症状,并且长期服用泻剂易导致结肠黑变病,甚至诱发结肠癌变等。
针对现有技术的不足,开发有效的、副作用小的用于治疗便秘,尤其针对老年及体虚患者的顽固性便秘、功能性便秘及肠道功能衰退的药物迫在眉睫。
发明内容
本发明要解决的技术问题是:提供一种治疗便秘的中药组合物,具有很好的通便作用,可有效治疗便秘,副作用小,尤其适合顽固性便秘、功能性便秘及肠道功能衰退的病人;本发明还提供其制备方法。
本发明所述的治疗便秘的中药组合物,由以下重量份数的原料制成:
所述中药组合物的药材基原如下:
七里香寄生为马钱科植物白背枫(Buddleja asiatica Lour.)之寄生。
地板藤寄生为桑科植物地石榴(Ficus tikoua Bur.)之寄生。
肉苁蓉为列当科植物肉苁蓉Cistanche deserticola Y.C.Ma的干燥带鳞叶的肉质茎。
当归为伞形科植物当归Angelica sinensis(Oliv.)Diels的干燥根。
枳壳为芸香科植物酸橙Citrus aurantium L.的干燥未成熟果实。
其中,七里香寄生性凉味苦,具有清热凉血、祛瘀消肿的功效,彝医用于治疗外伤止血,消炎、消肿,其化学成分及药理作用研究较少。地板藤寄生性凉味苦,具有清热解毒、除湿利尿、利湿的作用,彝医用于治疗感染。肉苁蓉性温味甘咸,具有补肾阳,益精血,润肠通便的功效,临床上用于治疗肾阳不足,精血亏虚,阳痿不孕,肠燥便秘等症,现代药理学研究表明,肉苁蓉通便的有效成分为总寡糖。当归性温味甘辛,具有补血活血、调经止痛、润肠通便的功效,临床用于治疗血虚萎黄,眩晕心悸,月经不调,经闭痛经,虚寒腹痛,风湿痹痛,跌扑操作,痈疽疮疡,肠燥便秘,现代药理学研究表明,当归通便的有效成分为当归多糖和当归油。枳壳性微寒味苦辛酸,具有理气宽中,行滞消胀的功效,用于治疗胸胁气滞,胀满疼痛,食积不化,痰饮内停,脏器下垂等症,现代药理学研究表明其所含的柚皮苷具有促进胃肠蠕动的作用。方中以七里香寄生及地板藤寄生性凉味苦、清热利水为君,主治腹胀两便不利;肉苁蓉、当归性温可缓和君药苦凉之力,兼有暖腰、润肠、养血之功,共为臣药;枳壳下气宽肠而助通便,为佐使。方中诸药合用,通便下气润肠,具有下不伤正、润而不腻、攻润相合的特点。
本发明所述的治疗便秘的中药组合物的制备方法,包括以下步骤:
(1)将七里香寄生、地板藤寄生渗漉提取,渗漉液减压浓缩后冷冻干燥;
(2)将肉苁蓉、当归、枳壳煎煮提取,提取液减压浓缩后低温真空干燥;
(3)将步骤(1)、(2)得到的提取物制备成所需的剂型。
所述剂型为口服液、片剂、胶囊剂或颗粒剂。
与现有技术相比,本发明有以下有益效果:
(1)本发明的治疗便秘的中药组合物不含蒽醌类及其衍生物,临床应用更安全;
(2)本发明的中药组合物通便作用明确,药效学试验结果显示本品颗粒能够促进正常小鼠的排便功能,提高正常小鼠或大鼠的肠推进功能,在体外能促进豚鼠离体回肠的收缩活动;
(3)本发明的中药组合物非容积性泻药,可适用于容积性泻药不适合的结肠无力、肠道运动功能差的患者;
(4)非临床安全性评价结果显示本发明的中药组合物未见毒副作用,可以避免泻剂依赖、泻剂结肠等不良反应,老年人、儿童服用较安全。
附图说明
图1为本发明所述中药组合物颗粒对正常小鼠排便时间的影响;
图2为本发明所述中药组合物颗粒对正常小鼠排便数量的影响;
图3为本发明所述中药组合物颗粒对正常小鼠肠推进百分率的影响;
图4为本发明所述中药组合物颗粒对正常小鼠肠管重量的影响;
图5为本发明所述中药组合物颗粒对大鼠大肠推进运动功能推进百分率的影响;
图6为本发明所述中药组合物颗粒对豚鼠离体回肠收缩活动最大张力的影响;
图7为本发明所述中药组合物颗粒对豚鼠离体回肠收缩活动收缩幅度的影响;
图8为本发明所述中药组合物颗粒对豚鼠离体回肠收缩活动的典型收缩曲线(终浓度0.25mg/ml);
图9为本发明所述中药组合物颗粒对豚鼠离体回肠收缩活动的典型收缩曲线(终浓度0.5mg/ml);
图10为本发明所述中药组合物颗粒对豚鼠离体回肠收缩活动的典型收缩曲线(终浓度1mg/ml);
图11为本发明所述中药组合物颗粒对豚鼠离体回肠收缩活动的典型收缩曲线(终浓度2mg/ml);
图12为本发明所述中药组合物颗粒对豚鼠离体回肠收缩活动的典型收缩曲线(终浓度4mg/ml);
图13为本发明所述中药组合物颗粒对豚鼠离体回肠收缩活动的典型收缩曲线(终浓度10mg/ml)。
具体实施方式
下面结合具体实施例对本发明进行进一步说明,不能理解为对本发明保护范围的限制,该领域的技术熟练人员可以根据上述内容对本发明做出一些非本质的改进和调整。
实施例1
本发明所述中药组合物颗粒剂的制备方法是按照以下步骤进行的:按照重量组分称取七里香寄生25份重量、地板藤寄生20份重量、肉苁蓉1份重量、当归1份重量、枳壳1份重量,将七里香寄生、地板藤寄生用70%乙醇渗漉提取,收集相当于七里香寄生和地板藤寄生重量总和10倍的渗漉液,渗漉液减压浓缩后冷冻干燥,粉碎,备用;取肉苁蓉、当归、枳壳加水煎煮提取2次,每次1小时,第一次加肉苁蓉、当归、枳壳重量总和8倍的水,第二次加肉苁蓉、当归、枳壳重量总和6倍的水,过滤,滤液减压浓缩后低温真空干燥,粉碎后与冻干粉混匀,加入适量辅料干法制粒,即得。
实施例2
本发明所述中药组合物片剂的制备方法是按照以下步骤进行的:按照重量组分称取七里香寄生40份重量、地板藤寄生15份重量、肉苁蓉5份重量、当归5份重量、枳壳3份重量,将七里香寄生、地板藤寄生用70%乙醇渗漉提取,收集相当于七里香寄生和地板藤寄生重量总和10倍的渗漉液,渗漉液减压浓缩后冷冻干燥,粉碎,备用;取肉苁蓉、当归、枳壳加水煎煮提取2次,每次1小时,第一次加肉苁蓉、当归、枳壳重量总和8倍的水,第二次加肉苁蓉、当归、枳壳重量总和6倍的水,过滤,滤液减压浓缩后低温真空干燥,粉碎后与冻干粉混匀,加入淀粉、硬脂酸镁适量,混匀,制粒,压片,包薄膜衣,即得。
实施例3
本发明所述中药组合物胶囊剂的制备方法是按照以下步骤进行的:按照重量组分称取七里香寄生30份重量、地板藤寄生18份重量、肉苁蓉2.5份重量、当归2.5份重量、枳壳1.5份重量,将七里香寄生、地板藤寄生用70%乙醇渗漉提取,收集相当于七里香寄生和地板藤寄生重量总和10倍的渗漉液,渗漉液减压浓缩后冷冻干燥,粉碎,备用;取肉苁蓉、当归、枳壳加水煎煮提取2次,每次1小时,第一次加肉苁蓉、当归、枳壳重量总和8倍的水,第二次加肉苁蓉、当归、枳壳重量总和6倍的水,过滤,滤液减压浓缩后低温真空干燥,粉碎后与冻干粉混匀,加入适量辅料,混匀,装入胶囊,即得。
实施例4:对本发明的中药组合物进行药效学试验。
1、实验材料
1.1药物与试剂
本发明所述中药组合物制备而成的颗粒,棕褐色颗粒,由瑞阳制药股份有限公司提供(实施例1)。
便通胶囊(阳性对照药),0.35g/粒,武汉健民药业集团股份有限公司产品。
曹素功高级油烟书画墨汁,上海周虎臣曹素功笔墨有限公司,规格:500ml/瓶。
活性炭,杭州木材厂产品。
1.2动物及饲养环境
ICR小鼠,SD大鼠,雌雄兼用,均由浙江省实验动物中心提供,许可证号:SCXK(浙)2014-0001号,饲养于本院动物房(清洁级),温度18~24℃,相对湿度60~80%,实验动物环境使用许可证号:SYXK(浙)2011-0166,全价颗粒饲料来源于浙江省实验动物中心;DHA系豚鼠,雌雄兼用,购自无锡市惠山江南实验动物场,实验动物质量许可证号:SCXK(苏)2015-0004。实验动物环境使用许可证号:SYXK(浙)2011-0166。
1.3仪器
MedLab-U/8c生物信号采集处理系统,南京美易科技有限公司产品;
BS 124 S电子天平,赛多利斯科学仪器(北京)有限公司。
1.4统计方法
所有计量数据均表示为mean±SD,检验方法为t检验,计数数据采用X2检验。
2、方法与结果
2.1对正常小鼠排便时间和数量的影响
ICR小鼠53只,体重20±2g,雌性,随机分为空白对照组、便通胶囊0.7g/kg阳性对照组以及本发明所述中药组合物颗粒3.3、6.6、13.2g/kg三个剂量组,每组10~11个,分别灌胃给予以蒸馏水配制并稀释的相应药物,每天1次,给药体积均为0.2ml/10g体重,空白对照组给予等体积蒸馏水,第6天末次给药前禁食约20h,末次给药时将所用药物用2%墨汁混悬液配制,空白对照组灌胃给予2%墨汁混悬液,给药容积均为0.2ml/10g体重。给药后将小鼠放入小鼠盒中,每盒1只,下垫白色干净滤纸,观察记录每只小鼠首次排出黑粪的时间(min)和4h内小鼠排出黑粪的总数(超过4h仍未排便的按240min计),结果见表1及图1~2。
表1本发明中药组合物颗粒对正常小鼠排便时间和数量的影响(X±SD)
注:*p<0.05(与空白对照组比较)
由表1、图1~2结果可见,本发明的中药组合物颗粒3.3、6.6、13.2g/kg剂量给予小鼠灌胃给药连续6天,可明显缩短首次黑粪时间,增加4h内黑粪粒数,与空白对照组相比均有统计学差异(P<0.05),并呈现明显的剂量效应关系,提示本发明所述中药组合物颗粒该剂量下能够促进正常小鼠的排便功能。
2.2对正常小鼠肠推进功能的影响
ICR小鼠54只,体重22±2g,雄性,随机分为空白对照组、便通胶囊0.7g/kg阳性对照组以及本发明所述中药组合物颗粒3.3、6.6、13.2g/kg三个剂量组,每组10~11个,分别灌胃给予以蒸馏水配制并稀释的相应药物,连续4天,给药体积均为0.2ml/10g体重,对照组给予等容积蒸馏水;第5天末次给药前禁食约12小时,末次给药后45分钟,灌胃给予0.1g/ml的活性炭末混悬液0.2ml/10g体重,20分钟后脱颈臼处死,测量小肠全长及炭末在小肠内推进距离,计算肠推进百分率(幽门至炭末推进前沿距离/小肠全长×100%),结果见表2、图3。
表2本发明所述中药组合物颗粒对正常小鼠肠推进功能的影响(X±SD)
注:*p<0.05(与空白对照组比较)
由表2、图3结果可见,本发明所述中药组合物颗粒3.3、6.6、13.2g/kg剂量给予小鼠灌胃给药连续5天,可明显增加炭末在小鼠小肠的推进距离,提高推进百分率,与空白对照组相比均有统计学差异(P<0.05),提示本发明所述中药组合物颗粒该剂量下能够提高正常小鼠的肠推进功能。
2.3对正常小鼠肠容积的影响
ICR小鼠50只,体重20±2g,雄性,随机分为正常对照组、便通胶囊1.4g/kg阳性对照组以及本发明所述中药组合物颗粒3.3、6.6、13.2g/kg三个剂量组,每组10个,分别灌胃给予以蒸馏水配制并稀释的相应药物,连续5天,给药体积均为0.2ml/10g体重,正常对照组给予等容积蒸馏水;末次给药前禁食约12小时,末次给药后2.5h将动物脱臼处死,剪开腹腔,暴露肠管,在幽门下端和回盲部结扎,自幽门处剪下肠管,小心用小剪刀沿肠管向下剪下肠系膜,在回盲部剪断肠管,于电子天平上准确称量肠管重量,结果见表3、图4。
表3本发明所述中药组合物颗粒对正常小鼠肠容积的影响(X±SD)
由表3、图4结果可见,本发明所述中药组合物颗粒3.3、6.6、13.2g/kg剂量给予小鼠灌胃给药连续5天,中、高剂量组肠管重量与正常对照组相比虽有增加的趋势,但无统计学差异(P>0.05),提示本发明所述中药组合物颗粒在该剂量下对正常小鼠肠容积无明显影响。由此可知,本发明所述中药组合物非容积性泻药,可适用于容积性泻药不适合的结肠无力、肠道运动功能差的患者。
2.4对大鼠大肠推进运动功能的影响
取体重300±50g健康成年SD大鼠,雄性,按体重随机分成分为空白对照组、便通胶囊0.5g/kg阳性对照组以及本发明所述中药组合物颗粒0.31、0.62、1.25g/kg三个剂量组,每组8~9个;实验时麻醉大鼠,然后腹部剪毛,沿正中线切口,打开腹腔找到盲肠与结肠连接处。空白对照组大鼠在该部向结肠腔内注入0.1g/ml活性炭末混悬液,给药组则注入含0.1g/ml活性炭末的药液,给药容积2.5ml/kg体重。给药后5min,立即打开腹腔,分离并剪下大肠,取出,自然摆直,用米尺测量大肠长度及炭末推进的距离,计算推进百分率,结果见表4、图5。
表4本发明所述中药组合物颗粒对大鼠大肠推进运动功能的影响(X±SD)
注:*p<0.05(与对照组比较)
由表4、图5结果可见,本发明所述中药组合物颗粒0.31、0.62、1.25g/kg剂量大鼠结肠给药1次,能不同程度地增加炭末在大鼠大肠的推进距离,提高推进百分率,其中1.25g/kg剂量组推进距离以及推进百分率与对照组相比有统计学差异(P<0.05),提示本发明所述中药组合物颗粒对正常大鼠的肠推进功能有一定的促进作用。
2.5对豚鼠离体回肠的影响
取DHA品系豚鼠,体重350±50g,雌雄兼用,禁食24小时,击头处死,取回肠1.5cm左右,置于盛有营养液的浴槽中,下端固定,上端与张力换能器相连,给予负荷张力0.5g,浴槽内并通氧气30个气泡/分钟,用MEDLAB生物信号采集分析系统记录正常肠管收缩曲线,然后按表5所示依次加入不同浓度的本发明所述中药组合物颗粒生理盐水混悬液;记录加药后肠管的收缩曲线,每次加药前均充分冲洗,并恢复至正常收缩曲线后试验,分别计算给药前后的最大张力及收缩幅度,结果见表5,图6~7,典型收缩曲线见附图8-13。
表5本发明所述中药组合物颗粒对豚鼠离体回肠收缩活动的影响(X±SD)
注:n=10,*p<0.05(与给药前比较)
从表5、图6~8结果可见,本发明所述中药组合物颗粒可促进离体豚鼠回肠的收缩幅度和张力,0.25~4mg/ml终浓度之间量效关系明确;与给药前比较,2、4、8mg/ml终浓度最大张力以及收缩幅度均显著增加(p<0.05),提示本发明所述中药组合物颗粒能促进豚鼠离体回肠的收缩活动。
3、结论
综上所述,本发明所述中药组合物颗粒能够促进正常小鼠的排便功能,提高正常小鼠或大鼠的肠推进功能,并能促进豚鼠离体回肠的收缩活动。由药效学结果可知,本发明所述中药组合物具有很好的通便作用。
实施例5:对本发明的中药组合物的安全性分析及评价
为了充分暴露受试物毒性,非临床安全性评价中均采用啮齿类动物大鼠作为试验对象,研究本发明所述中药组合物颗粒的单次给药毒性和重复给药毒性,以期获得较为充分的安全性信息。给药途径选择经口给药,与临床用药途径相一致。
本试验设计急性毒性试验的剂量为25g/kg/d,约为大鼠等效临床剂量的9.3倍;重复给药毒性试验中低、中、高剂量分别为4.68、9.36、18.75g/kg/d,分别约为大鼠等效临床剂量的1.7倍、3.5倍和6.9倍,分别为临床拟用剂量的9.4倍、18.7倍和37.5倍。
经口给予SD大鼠本发明所述中药组合物颗粒12.5g/kg,一日2次给药,给药间隔约5小时。每天观察动物的外观体征、行为活动、呼吸、大小便等情况。药后所有动物未见明显异常,继续观察至14天,大鼠一般状态良好,体重增长正常,剖检所有动物,肉眼形态学观察结果均未见明显异常改变。可见,本发明所述中药组合物颗粒急性给药不能引起大鼠毒副作用,本品最大耐受剂量大于25g/kg/d。
经口重复给予SD大鼠4.68、9.36、18.75g/kg/d的本发明所述中药组合物颗粒,每天给药2次,连续给药13周,并停药恢复观察4周。观察和检测相关指标。给药结束和恢复期结束剖检动物,进行肉眼病理学检查和组织病理学检查。结果可知,给药期间和恢复期内动物一般状况良好,自主活动正常,未见异常反应,与空白对照相比,给药组动物进食量有一过性降低,给药结束后即恢复,推测与给药体积较大,给药时间较长有关。试验中有4只动物死亡,解剖结果显示可能与灌胃操作失误有关,与药物毒性无关。与空白对照相比,给药动物血液学指标、血清生化指标、脏器重量和脏器系数等出现一些明显的改变,但是无剂量依赖性,或在正常范围内波动,故无毒理学意义。给药后动物凝血指标无改变。动物肉眼病理学结果和组织病理学结果均未出现与给药相关的改变。总之,在高达临床拟用剂量的37.5倍时,本发明所述中药组合物颗粒重复给药13周不能引起大鼠毒副作用。
从一般药理学研究文献可知,本发明所述中药组合物颗粒中各药材对动物中枢神经系统、心血管系统和呼吸系统都不产生明显的影响,结合大鼠急性毒性试验和重复给药毒性试验结果,可见本发明所述中药组合物颗粒在较高的给药剂量下几乎没有毒副作用,这为该药的临床开发应用提供了安全依据。
Claims (8)
2.根据权利要求1所述的治疗便秘的中药组合物,其特征在于:七里香寄生为马钱科植物白背枫之寄生。
3.根据权利要求1所述的治疗便秘的中药组合物,其特征在于:地板藤寄生为桑科植物地石榴之寄生。
4.根据权利要求1所述的治疗便秘的中药组合物,其特征在于:肉苁蓉为列当科植物肉苁蓉的干燥带鳞叶的肉质茎。
5.根据权利要求1所述的治疗便秘的中药组合物,其特征在于:当归为伞形科植物当归的干燥根。
6.根据权利要求1所述的治疗便秘的中药组合物,其特征在于:枳壳为芸香科植物酸橙的干燥未成熟果实。
7.一种权利要求1-6任一项所述的治疗便秘的中药组合物的制备方法,其特征在于:包括以下步骤:
(1)将七里香寄生、地板藤寄生渗漉提取,渗漉液减压浓缩后冷冻干燥;
(2)将肉苁蓉、当归、枳壳煎煮提取,提取液减压浓缩后低温真空干燥;
(3)将步骤(1)、(2)得到的提取物制备成所需的剂型。
8.根据权利要求7所述的治疗便秘的中药组合物的制备方法,其特征在于:所述剂型为口服液、片剂、胶囊剂或颗粒剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110919165.9A CN113440557B (zh) | 2021-08-11 | 2021-08-11 | 用于治疗便秘的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110919165.9A CN113440557B (zh) | 2021-08-11 | 2021-08-11 | 用于治疗便秘的中药组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113440557A true CN113440557A (zh) | 2021-09-28 |
CN113440557B CN113440557B (zh) | 2023-07-11 |
Family
ID=77818410
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110919165.9A Active CN113440557B (zh) | 2021-08-11 | 2021-08-11 | 用于治疗便秘的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113440557B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040010854A (ko) * | 2002-07-25 | 2004-02-05 | 서울향료(주) | 생약소재에 의한 변비 개선용 농축액 및 그 제조방법과용도 |
CN102283955A (zh) * | 2010-06-17 | 2011-12-21 | 苏州知微堂生物科技有限公司 | 一种济川煎整合型新剂型制备技术及其生产方法 |
CN111084837A (zh) * | 2020-02-12 | 2020-05-01 | 长春中医药大学 | 一种治疗慢传输型便秘的中药组合物及其制备方法 |
CN113181292A (zh) * | 2021-05-20 | 2021-07-30 | 南京正宽医药科技有限公司 | 一种用于治疗便秘的中药组合物 |
-
2021
- 2021-08-11 CN CN202110919165.9A patent/CN113440557B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040010854A (ko) * | 2002-07-25 | 2004-02-05 | 서울향료(주) | 생약소재에 의한 변비 개선용 농축액 및 그 제조방법과용도 |
CN102283955A (zh) * | 2010-06-17 | 2011-12-21 | 苏州知微堂生物科技有限公司 | 一种济川煎整合型新剂型制备技术及其生产方法 |
CN111084837A (zh) * | 2020-02-12 | 2020-05-01 | 长春中医药大学 | 一种治疗慢传输型便秘的中药组合物及其制备方法 |
CN113181292A (zh) * | 2021-05-20 | 2021-07-30 | 南京正宽医药科技有限公司 | 一种用于治疗便秘的中药组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN113440557B (zh) | 2023-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100471511C (zh) | 一种用于治疗便秘的药物组合物 | |
CN1985922B (zh) | 一种治疗感冒的药物组合物及其制备方法 | |
CN102475835A (zh) | 一种治疗小儿感冒或感冒后咳嗽的药物组合物及其制备方法 | |
CN104352608B (zh) | 一种益气活血、软坚散结、解毒止痛的中药及其制备方法 | |
CN103933450A (zh) | 一种预防或/和治疗胃肠疾病的中药组合物及其制备方法 | |
CN101104018A (zh) | 一种治疗胃病的药物组合物及其制备方法 | |
CN108721431B (zh) | 一种排重金属的中药组合物及其应用 | |
CN102133273A (zh) | 一种中药降脂通便胶囊及其制备方法 | |
CN113440557A (zh) | 用于治疗便秘的中药组合物及其制备方法 | |
CN102274394A (zh) | 一种治疗产后便秘的中药组合物 | |
CN101167734A (zh) | 双向调节胃肠道平滑肌收缩的组合物 | |
JP7157253B2 (ja) | 潤腸便通の漢方薬組成物、その調製方法及びその用途 | |
KR20090131577A (ko) | 글루코사민과 생약재 혼합물을 포함하는 약학 제제 | |
CN101199806A (zh) | 一种治疗腹泻的药物及其制备方法和质量控制方法 | |
CN104257809B (zh) | 一种治疗便秘藏药的制备方法 | |
CN107260851B (zh) | 一种治疗虚性便秘的中药组合物 | |
CN103191243B (zh) | 由黄连、吴茱萸组成的药物组合物的用途及其制备方法 | |
CN103316124B (zh) | 生大黄组合物在通腑理气和肠道恢复的用途 | |
CN113476562A (zh) | 一种组合物及其制备方法和用途 | |
CN106581236A (zh) | 一种促进胃动力的药物组合物及其制备方法和应用 | |
CN102526211B (zh) | 一种治疗便秘口服药物的组方及制备工艺 | |
CN108704036A (zh) | 一种治疗痛风的复方中药制剂及其制备方法 | |
CN115025178B (zh) | 一种兰花草提取物在制备预防和/或治疗便秘药物中的应用 | |
CN100396294C (zh) | 阿魏挥发油在制备肠易激综合症药剂中的应用 | |
CN102688325B (zh) | 用于胃肠病的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Hu Qingwen Inventor after: Miao Dezu Inventor after: Jiao Qiyang Inventor after: Cao Guidong Inventor before: Miao Dezu Inventor before: Hu Qingwen Inventor before: Jiao Qiyang Inventor before: Cao Guidong |
|
CB03 | Change of inventor or designer information |